The Schizophrenia Research Service (SRS)
Schizophrenia and other psychotic illnesses represent a major burden to the health care system and, more importantly, to the patients and their families who experience and live with the illness. The SRS is dedicated to research that will enhance understanding of schizophrenia and its treatment. Our primary focus is on studies of newer medications that may improve long term outcome or improve recovery. We also conduct studies that examine treatment settings and conduct secondary analyses of data characterize patients that contribute to improved or poorer outcomes. The Service aims to offer research participants excellent clinical care based on current knowledge while at the same time advancing our knowledge of how to better treat this devastating illness. The mission of the SRS is highly congruent with the overall mission of the Department of Psychiatry and Behavioral Sciences at SUNY Downstate.
Current Research Projects:
- Treatment of schizophrenia patients with a new long-acting injectable medication - aripiprazole IM depot: a six-month observational study (PI Stephen Goldfinger, MD)
- A Phase-II study of a medication (NBI-98854) for treatment of tardive dyskinesia (PI Abdel Elmouchtari, MD)
- Recovery After an Initial Schizophrenia Episode – Early Treatment Program (RAISE-ETP) – a multi-center study of an integrated treatment for first episode psychosis (PI Nina Schooler, PhD)
In addition to the above studies, the Schizophrenia Research Service is an integral part of the teaching and consultation services for schizophrenia and related psychotic disorders. Residents have the opportunity to participate in weekly SRS meetings and projects, gaining skills in assessment, data collection, standardized evaluation techniques and manuscript preparation as well as hands-on experience in research conduct and training in research assessment.
Schizophrenia Research Service Faculty
Nina Schooler, PhD